Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 7
2020 17
2021 23
2022 25
2023 24
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Factors Associated With an Electronic Health Record-Based Definition of Postacute Sequelae of COVID-19 in Patients With Systemic Autoimmune Rheumatic Disease.
Patel NJ, Wang X, Lin M, Kowalski EN, Cook CE, Vanni KMM, Guzzo K, Qian G, Bade KJ, Saavedra A, Venkat R, Srivatsan S, Williams ZK, Hanberg JS, Kawano Y, Schiff AE, Sparks JA, Wallace ZS. Patel NJ, et al. J Rheumatol. 2024 May 1;51(5):529-537. doi: 10.3899/jrheum.2023-1092. J Rheumatol. 2024. PMID: 38428964 Free article.
Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial.
Hanberg JS, Fu X, Wang X, Patel NJ, Kawano Y, Schiff A, Kowalski EN, Cook CE, Vanni KMM, Guzzo K, Qian G, Bade KJ, Saavedra A, Venkat R, Srivatsan S, Zhang Y, Sparks JA, Wallace ZS. Hanberg JS, et al. Lancet Rheumatol. 2024 Jan;6(1):e21-e30. doi: 10.1016/S2665-9913(23)00272-2. Epub 2023 Nov 15. Lancet Rheumatol. 2024. PMID: 38258675 Clinical Trial.
Immunomodulators and risk for breakthrough COVID-19 after third SARS-CoV-2 mRNA vaccine among patients with rheumatoid arthritis: a cohort study.
Schiff AE, Wang X, Patel NJ, Kawano Y, Hanberg JL, Kowalski EN, Cook CE, Vanni KM, Qian G, Bade KJ, Saavedra AA, Srivatsan S, Williams ZK, Venkat RK, Wallace ZS, Sparks JA. Schiff AE, et al. Ann Rheum Dis. 2024 Apr 11;83(5):680-682. doi: 10.1136/ard-2023-225162. Ann Rheum Dis. 2024. PMID: 38199795 No abstract available.
Immunomodulators and risk for breakthrough infection after third COVID-19 mRNA vaccine among patients with rheumatoid arthritis: A cohort study.
Schiff AE, Wang X, Patel NJ, Kawano Y, Kowalski EN, Cook CE, Vanni KMM, Qian G, Bade KJ, Saavedra AA, Srivatsan S, Williams ZK, Venkat RK, Wallace ZS, Sparks JA. Schiff AE, et al. medRxiv [Preprint]. 2023 Oct 9:2023.10.08.23296717. doi: 10.1101/2023.10.08.23296717. medRxiv. 2023. PMID: 37873462 Free PMC article. Updated. Preprint.
Humoral immunity to an endemic coronavirus is associated with postacute sequelae of COVID-19 in individuals with rheumatic diseases.
Herman JD, Atyeo C, Zur Y, Cook CE, Patel NJ, Vanni KM, Kowalski EN, Qian G, Srivatsan S, Shadick NA, Rao DA, Kellman B, Mann CJ, Lauffenburger D, Wallace ZS, Sparks JA, Alter G. Herman JD, et al. Sci Transl Med. 2023 Sep 6;15(712):eadf6598. doi: 10.1126/scitranslmed.adf6598. Epub 2023 Sep 6. Sci Transl Med. 2023. PMID: 37672567 Free PMC article.
Assessment of patient-reported symptoms and distress in IgG4-related disease (IgG4-RD): Development, clinical validation, and content validation of the IgG4-RD Symptom Severity Index.
Wallace ZS, McMahon GA, Hang B, Fu X, Harkness T, Donelan K, Fernandes A, Cook C, Katz G, Perugino C, Stone JH. Wallace ZS, et al. Semin Arthritis Rheum. 2023 Dec;63:152253. doi: 10.1016/j.semarthrit.2023.152253. Epub 2023 Aug 18. Semin Arthritis Rheum. 2023. PMID: 37619485
83 results